Matthew J. Sikora, PhD Profile picture
Breast cancer scientist. Asst Prof @CUAnschutz. Studying endocrine rx response & resistance, focus on #lobular BrCa. Tweets are my own. He/Him. Lab: @SikoraLab
Jan 17, 2019 10 tweets 4 min read
Clinical trials design for #lobular #breastcancer patients are finally available! Let's look for a moment at the Pitt Neoadjuvant Endocrine therapy trial.
lobularbreastcancer.org/clinical-trial…
#bcsm 1/ In this trial, patients will be treated before surgery for 21 days with tamoxifen, anastrozole, or fulvestrant (all current drugs that target the estrogen receptor).

You might say, it's a short treatment without any new fancy drugs. What's important about this trial? 2/